Certara Reports Fourth Quarter 2024 Financial Results
Certara (NASDAQ: CERT) reported strong Q4 2024 financial results with total revenue of $100.4 million, up 14% year-over-year. The company's performance was marked by significant growth across segments, with software revenue increasing 26% to $42.3 million and services revenue growing 7% to $58.1 million.
Notable achievements include a net income of $6.6 million, compared to a previous year's loss of $12.5 million, and adjusted EBITDA of $33.5 million, representing 13% growth. Total bookings reached $144.5 million, up 22%, with software bookings growing 38% to $59.7 million.
Looking ahead, Certara provided 2025 guidance projecting revenue between $415-425 million, with adjusted EBITDA margin of 30-32% and adjusted diluted EPS of $0.42-$0.46.
Certara (NASDAQ: CERT) ha riportato risultati finanziari solidi per il quarto trimestre del 2024, con un fatturato totale di 100,4 milioni di dollari, in aumento del 14% rispetto all'anno precedente. Le performance dell'azienda sono state caratterizzate da una crescita significativa in tutti i segmenti, con i ricavi da software in aumento del 26% a 42,3 milioni di dollari e i ricavi da servizi in crescita del 7% a 58,1 milioni di dollari.
Tra i risultati notevoli si evidenzia un utile netto di 6,6 milioni di dollari, rispetto a una perdita di 12,5 milioni di dollari dell'anno precedente, e un EBITDA rettificato di 33,5 milioni di dollari, che rappresenta una crescita del 13%. Le prenotazioni totali hanno raggiunto 144,5 milioni di dollari, in aumento del 22%, con le prenotazioni software in crescita del 38% a 59,7 milioni di dollari.
Guardando al futuro, Certara ha fornito stime per il 2025 prevedendo un fatturato tra 415-425 milioni di dollari, con un margine EBITDA rettificato del 30-32% e un utile per azione diluito rettificato di 0,42-0,46 dollari.
Certara (NASDAQ: CERT) informó resultados financieros sólidos para el cuarto trimestre de 2024, con ingresos totales de 100,4 millones de dólares, un aumento del 14% en comparación con el año anterior. El rendimiento de la empresa se caracterizó por un crecimiento significativo en todos los segmentos, con ingresos por software que aumentaron un 26% a 42,3 millones de dólares y los ingresos por servicios creciendo un 7% a 58,1 millones de dólares.
Entre los logros notables se incluye un ingreso neto de 6,6 millones de dólares, en comparación con una pérdida de 12,5 millones de dólares del año anterior, y un EBITDA ajustado de 33,5 millones de dólares, lo que representa un crecimiento del 13%. Las reservas totales alcanzaron 144,5 millones de dólares, un aumento del 22%, con las reservas de software creciendo un 38% a 59,7 millones de dólares.
De cara al futuro, Certara proporcionó una guía para 2025 proyectando ingresos entre 415-425 millones de dólares, con un margen de EBITDA ajustado del 30-32% y un EPS diluido ajustado de 0,42-0,46 dólares.
Certara (NASDAQ: CERT)는 2024년 4분기 재무 결과를 발표하며 총 수익이 1억 4백만 달러로 전년 대비 14% 증가했다고 보고했습니다. 회사의 성과는 모든 부문에서의 상당한 성장으로 특징지어졌으며, 소프트웨어 수익이 26% 증가하여 4,230만 달러에 달하고, 서비스 수익은 7% 증가하여 5,810만 달러에 도달했습니다.
주목할 만한 성과로는 660만 달러의 순이익이 있으며, 이는 전년도에 1,250만 달러의 손실에서 개선된 수치입니다. 조정된 EBITDA는 3,350만 달러로, 13% 성장한 수치입니다. 총 예약은 1억 4,450만 달러에 이르렀으며, 이는 22% 증가한 수치로, 소프트웨어 예약은 38% 증가하여 5,970만 달러에 달했습니다.
앞으로 Certara는 2025년 예상 수익을 4억 1,500-4억 2,500만 달러로 전망하며, 조정된 EBITDA 마진은 30-32%, 조정된 희석 EPS는 0.42-0.46 달러로 예상했습니다.
Certara (NASDAQ: CERT) a annoncé de solides résultats financiers pour le quatrième trimestre 2024, avec des revenus totaux de 100,4 millions de dollars, en hausse de 14 % par rapport à l'année précédente. La performance de l'entreprise a été marquée par une croissance significative dans tous les segments, avec des revenus logiciels en hausse de 26 % à 42,3 millions de dollars et des revenus de services en hausse de 7 % à 58,1 millions de dollars.
Parmi les réalisations notables, on peut citer un bénéfice net de 6,6 millions de dollars, contre une perte de 12,5 millions de dollars l'année précédente, et un EBITDA ajusté de 33,5 millions de dollars, représentant une croissance de 13 %. Les réservations totales ont atteint 144,5 millions de dollars, en hausse de 22 %, avec des réservations logicielles en croissance de 38 % à 59,7 millions de dollars.
En regardant vers l'avenir, Certara a fourni des prévisions pour 2025, projetant des revenus entre 415-425 millions de dollars, avec une marge EBITDA ajustée de 30-32 % et un bénéfice par action dilué ajusté de 0,42-0,46 dollar.
Certara (NASDAQ: CERT) berichtete über starke finanzielle Ergebnisse für das vierte Quartal 2024 mit einem Gesamtumsatz von 100,4 Millionen Dollar, was einem Anstieg von 14% im Vergleich zum Vorjahr entspricht. Die Leistung des Unternehmens war durch ein signifikantes Wachstum in allen Segmenten gekennzeichnet, wobei die Softwareumsätze um 26% auf 42,3 Millionen Dollar stiegen und die Dienstleistungsumsätze um 7% auf 58,1 Millionen Dollar wuchsen.
Zu den bemerkenswerten Erfolgen gehören ein Nettogewinn von 6,6 Millionen Dollar, verglichen mit einem Verlust von 12,5 Millionen Dollar im Vorjahr, sowie ein bereinigtes EBITDA von 33,5 Millionen Dollar, was einem Wachstum von 13% entspricht. Die Gesamtbuchungen erreichten 144,5 Millionen Dollar, was einem Anstieg von 22% entspricht, wobei die Softwarebuchungen um 38% auf 59,7 Millionen Dollar zulegten.
Für die Zukunft gab Certara eine Prognose für 2025 heraus, die einen Umsatz zwischen 415-425 Millionen Dollar vorsieht, mit einer bereinigten EBITDA-Marge von 30-32% und einem bereinigten verwässerten EPS von 0,42-0,46 Dollar.
- Revenue growth of 14% to $100.4M
- Software revenue up 26% to $42.3M
- Total bookings increased 22% to $144.5M
- Turned $12.5M loss into $6.6M profit
- Adjusted EBITDA grew 13% to $33.5M
- Services revenue growth slowed to 7%
- Expected EBITDA margins to remain in low 30s for 2025
- Mixed operating environment noted by management
Insights
Certara delivered robust Q4 2024 results with revenue reaching
The company's return to profitability is particularly noteworthy, with net income of
Bookings metrics provide encouraging forward visibility – total bookings grew
The Chemaxon acquisition appears to be exceeding management expectations, contributing
Management's 2025 guidance of
Investors should monitor software growth rates and Chemaxon integration progress as key indicators of Certara's success in expanding their technological moat in this specialized niche of the pharmaceutical technology ecosystem.
Certara's strong Q4 results underscore the accelerating adoption of biosimulation technology in pharmaceutical R&D, with their software revenue jumping
The Chemaxon acquisition strategically extends Certara's capabilities upstream in the drug development process. While Certara's core platforms like Simcyp and Phoenix focus on clinical pharmacology and pharmacokinetics, Chemaxon adds critical cheminformatics capabilities for early-stage drug discovery. This creates a more comprehensive technology stack that can capture more of the
Management's emphasis on AI investment is particularly significant as machine learning approaches are transforming biosimulation. Traditional pharmacokinetic models are being enhanced with AI to improve predictive accuracy from
The software bookings surge of
Certara's technology value proposition centers on de-risking clinical trials, which have failure rates exceeding
As AI continues transforming drug discovery and development, Certara's position at this critical technology intersection provides significant growth runway, though maintaining technological leadership will require sustained R&D investment against emerging competitors.
Issues Full Year 2025 Financial Guidance
RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024.
Fourth Quarter Highlights:
- Revenue was
$100.4 million , compared to$88.0 million in the fourth quarter of 2023, representing growth of14% .- Software revenue was
$42.3 million , compared to$33.6 million in the fourth quarter of 2023, representing growth of26% . - Services revenue was
$58.1 million , compared to$54.4 million in the fourth quarter of 2023, representing growth of7% .
- Software revenue was
- Net income was
$6.6 million , compared to a net loss of$12.5 million in the fourth quarter of 2023. - Adjusted EBITDA was
$33.5 million , compared to$29.6 million in the fourth quarter of 2023, representing growth of13% .
"We are pleased with our fourth quarter results, which reflect solid performance in our core biosimulation business and contribution from Chemaxon that was ahead of our expectations," said William F. Feehery, Chief Executive Officer. “In 2025, we will continue to invest in software and AI, strengthening our end-to-end biosimulation offering that spans from drug discovery through the clinic. We are well positioned to capitalize on the growing interest in biosimulation technology across the global biopharmaceutical industry and are confident that our investment strategy will yield strong returns for our shareholders over the coming years."
"Our commercial team executed according to our plan in the fourth quarter, driving strong bookings across both software and services despite a mixed operating environment. Our initial expectation is that our end markets this year will be similar to what we experienced in 2024. We expect adjusted EBITDA margins will remain in the low thirties in 2025, as we continue to invest in R&D and integrate Chemaxon." said John Gallagher, Chief Financial Officer.
Fourth Quarter 2024 Results
Total revenue for the fourth quarter of 2024 was
Software revenue for the fourth quarter of 2024 was
Services revenue for the fourth quarter of 2024 was
Total Bookings for the fourth quarter of 2024 were
Software Bookings for the fourth quarter of 2024 were
Services Bookings for the fourth quarter of 2024 were
Total cost of revenue for the fourth quarter of 2024 was
Total operating expenses for the fourth quarter of 2024 were
Adjusted EBITDA for the fourth quarter of 2024 was
Diluted earnings per share for the fourth quarter 2024 was
Net income for the fourth quarter of 2024 was
Adjusted net income for the fourth quarter of 2024 was
| THREE MONTHS ENDED DECEMBER 31, | TWELVE MONTHS ENDED DECEMBER 31, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||
| Key Financials | (in millions, except per share data) | |||||||||||||
| Revenue | $ | 100.4 | $ | 88.0 | $ | 385.1 | $ | 354.3 | ||||||
| Software revenue | $ | 42.3 | $ | 33.6 | $ | 155.7 | $ | 131.7 | ||||||
| Service revenue | $ | 58.1 | $ | 54.4 | $ | 229.5 | $ | 222.7 | ||||||
| Total bookings | $ | 144.5 | $ | 118.9 | $ | 445.3 | $ | 402.3 | ||||||
| Software bookings | $ | 59.7 | $ | 43.3 | $ | 169.4 | $ | 136.9 | ||||||
| Service bookings | $ | 84.8 | $ | 75.6 | $ | 275.9 | $ | 265.4 | ||||||
| Net income (loss) | $ | 6.6 | $ | (12.5 | ) | $ | (12.1 | ) | $ | (55.4 | ) | |||
| Diluted earnings per share | $ | 0.04 | $ | (0.08 | ) | $ | (0.08 | ) | $ | (0.35 | ) | |||
| Adjusted EBITDA | $ | 33.5 | $ | 29.6 | $ | 122.0 | $ | 123.1 | ||||||
| Adjusted net income | $ | 24.7 | $ | 14.3 | $ | 72.9 | $ | 69.0 | ||||||
| Adjusted diluted earnings per share | $ | 0.15 | $ | 0.09 | $ | 0.45 | $ | 0.43 | ||||||
| Cash and cash equivalents | $ | 179.2 | $ | 235.0 | ||||||||||
2025 Financial Outlook
Certara is providing its guidance for the full year 2025. We expect the following:
- Full year 2025 revenue to be in the range of
$415 million to$425 million . - Full year adjusted EBITDA margin to be in the range of 30
-32% . - Full year adjusted diluted earnings per share is expected to be in the range of
$0.42 -$0.46 . - Fully diluted shares are expected to be in the range of 162 million to 164 million.
Webcast and Conference Call Details
Certara will host a conference call today, February 26, 2025, at 5:00 p.m. ET to discuss its fourth quarter 2024 financial results. Investors interested in listening to the conference call are required to register online in advance of the call. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com.
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.
Please visit our website at www.certara.com. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.
Such disclosures will be included in the Investor Relations section of our website at https://ir.certara.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, Securities and Exchange Commission filings and public conference calls and webcasts.
Forward-Looking Statements
This press release contains certain statements that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, with respect to the Company’s full-year guidance and other statements about the Company’s future business and financial performance, revenue, margin, and bookings. These statements typically contain words such as “believe,” “may,” “potential,” “will,” “plan,” “could,” “estimate,” “expects” and “anticipates” or the negative of these words or other similar terms or expressions. Any statement in this press release that is not a statement of historical fact is a forward-looking statement and involves significant risks and uncertainties. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot provide any assurance that these expectations will prove to be correct. You should not rely upon forward-looking statements as predictions of future events and actual results, events, or circumstances. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the Company’s ability to compete within its market; any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery; changes or delays in relevant government regulation; increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; economic conditions, including inflation, recession, currency exchange fluctuation and adverse developments in the financial services industry; trends in research and development (R&D) spending; delays or cancellations in projects due to supply chain interruptions or disruptions or delays to pipeline development and clinical trials experienced by our customers; consolidation within the biopharmaceutical industry; reduction in the use of the Company’s products by academic institutions; pricing pressures; the Company’s ability to successfully enter new markets, increase its customer base and expand its relationships with existing customers; the impact of acquisitions and our ability to successfully integrate such acquisitions; the occurrence of natural disasters and epidemic diseases; any delays or defects in the release of new or enhanced software or other biosimulation tools; failure of our existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by its existing customers; our ability to accurately estimate costs associated with its fixed-fee contracts; our ability to retain key personnel or recruit additional qualified personnel; risks related to the mischaracterization of our independent contractors; lower utilization rates by our employees as a result of natural disasters and epidemic diseases; risks related to our contracts with government customers; our ability to sustain recent growth rates; our ability to successfully operate a global business; our ability to comply with applicable laws and regulations; risks related to litigation; the adequacy of its insurance coverage and ability to obtain adequate insurance coverage in the future; our ability to perform in accordance with contractual requirements, regulatory standards and ethical considerations; the loss of more than one of our major customers; future capital needs; the ability of our bookings to accurately predict future revenue and our ability to realize revenue on bookings; disruptions in the operations of the third-party providers who host our software solutions or any limitations on their capacity; our ability to reliably meet data storage and management requirements, or the experience of any failures or interruptions in the delivery of our services over the internet; our ability to comply with the terms of any licenses governing use of third-party open source software; any breach of its security measures or unauthorized access to customer data; risks relating to the use of artificial intelligence and machine learning in our products and services; our ability to adequately enforce or defend ownership and use of our intellectual property and other proprietary rights; any allegations of infringement, misappropriation or violations of a third party’s intellectual property rights; our ability to meet obligations under indebtedness and have sufficient capital to operate our business; any limitations on our ability to pursue business strategies due to restrictions under our current or future indebtedness; any additional impairment of goodwill or other intangible assets; our ability to use our net operating losses and R&D tax credit carryforwards; the accuracy of management’s estimates and judgments relating to critical accounting policies and changes in financial reporting standards or interpretations; any inability to design, implement, and maintain effective internal controls or inability to remediate any internal controls deemed ineffective; the costs and management time associated with operating as a publicly traded company; and the other factors detailed under the captions “Risk Factors” and “Special Note Regarding Forward-Looking Statements” and elsewhere in our Securities and Exchange Commission (“SEC”) filings, and reports, including the Form 10-K filed by the Company with the Securities and Exchange Commission on February 29, 2024, and subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events.
A Note on Non-GAAP Financial Measures
This press release contains “non-GAAP measures” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Specifically, the Company makes use of the non-GAAP financial measures adjusted EBITDA, adjusted net income (loss), adjusted diluted earnings per share, and constant currency (“CC”) revenue, which are not recognized terms under GAAP. These measures should not be considered as alternatives to net income (loss) or GAAP diluted earnings per share or revenue as measures of financial performance or any other performance measure derived in accordance with GAAP and should not be considered a measure of discretionary cash available to the Company to invest in the growth of its business. The presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the Company’s results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.
You should refer to the footnotes below as well as the “Non-GAAP Financial Measures” section in this press release below for a further explanation of these measures and reconciliations of these non-GAAP measures in specific periods to their most directly comparable financial measure calculated and presented in accordance with GAAP for those periods.
Management uses various financial metrics, including total revenues, income (loss) from operations, net income (loss), and certain non-GAAP measures, including those discussed above, to measure and assess the performance of the Company’s business, to evaluate the effectiveness of its business strategies, to make budgeting decisions, to make certain compensation decisions, and to compare the Company’s performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures for period-to-period comparisons of the Company’s business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance.
Management believes that adjusted EBITDA, adjusted net income (loss), adjusted diluted earnings per share, and CC revenue are helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, each of these measures is frequently used by analysts, investors, and other interested parties to evaluate and assess performance. Furthermore, our business has operations outside the United States that are conducted in local currencies. As a result, the comparability of the financial results reported in U.S. dollars is affected by changes in foreign currency exchange rates. We adjust revenues for constant currency to provide a framework for assessing how our business performed excluding the effect of foreign currency rate fluctuations and we believe it is helpful for investors to present operating results on a comparable basis period over period to evaluate its underlying performance.
Please note that the Company has not reconciled the adjusted EBITDA or adjusted diluted earnings per share forward-looking guidance included in this press release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.
| (1) | CC revenue excludes the effects of foreign currency exchange rate fluctuations by assuming constant foreign currency exchange rates used for translation. Current periods revenue reported in currencies other than U.S. Dollars are converted into U.S. Dollars at the average exchange rates in effect for the comparable prior periods. |
| (2) | Adjusted EBITDA represents net income excluding interest expense, provision (benefit) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, goodwill impairment, change in fair value of contingent consideration, acquisition and integration expense and other items not indicative of our ongoing operating performance. |
| (3) | Adjusted net income and adjusted diluted earnings per share exclude the effect of equity-based compensation expense, amortization of acquisition-related intangible assets, goodwill impairment, change in fair value of contingent consideration, acquisition and integration expense, and other items not indicative of our ongoing operating performance as well as income tax provision adjustment for such charges. |
In evaluating adjusted EBITDA, adjusted net income, and adjusted diluted earnings per share, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.
Contacts:
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Alyssa Horowitz
Pan Communications
certara@pancomm.com
| CERTARA, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | ||||||||||||||||
| THREE MONTHS ENDED DECEMBER 31, | TWELVE MONTHS ENDED DECEMBER 31, | |||||||||||||||
| (IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Total revenues | $ | 100,361 | $ | 88,010 | $ | 385,148 | $ | 354,337 | ||||||||
| Cost of revenues | 38,263 | 34,066 | 154,516 | 141,022 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Sales and marketing | 13,197 | 8,671 | 47,444 | 32,022 | ||||||||||||
| Research and development | 7,772 | 8,018 | 37,105 | 34,173 | ||||||||||||
| General and administrative | 21,141 | 33,608 | 94,221 | 95,385 | ||||||||||||
| Intangible asset amortization | 13,313 | 11,701 | 51,599 | 43,973 | ||||||||||||
| Depreciation and amortization expense | 672 | 413 | 1,994 | 1,552 | ||||||||||||
| Goodwill impairment expense | — | — | — | 46,984 | ||||||||||||
| Total operating expenses | 56,095 | 62,411 | 232,363 | 254,089 | ||||||||||||
| Income (loss) from operations | 6,003 | (8,467 | ) | (1,731 | ) | (40,774 | ) | |||||||||
| Other income (expenses): | ||||||||||||||||
| Interest expense | (5,004 | ) | (5,870 | ) | (21,520 | ) | (22,916 | ) | ||||||||
| Net other income | 1,181 | 1,953 | 6,067 | 8,547 | ||||||||||||
| Total other expenses | (3,823 | ) | (3,917 | ) | (15,453 | ) | (14,369 | ) | ||||||||
| Income (loss) before income taxes | 2,180 | (12,384 | ) | (17,184 | ) | (55,143 | ) | |||||||||
| Provision (benefit) for income taxes | (4,397 | ) | 72 | (5,133 | ) | 214 | ||||||||||
| Net income (loss) | $ | 6,577 | $ | (12,456 | ) | $ | (12,051 | ) | $ | (55,357 | ) | |||||
| Net income (loss) per share attributable to common stockholders: | ||||||||||||||||
| Basic | $ | 0.04 | $ | (0.08 | ) | $ | (0.08 | ) | $ | (0.35 | ) | |||||
| Diluted | $ | 0.04 | $ | (0.08 | ) | $ | (0.08 | ) | $ | (0.35 | ) | |||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | 160,891,458 | 159,430,660 | 160,392,805 | 158,936,251 | ||||||||||||
| Diluted | 161,265,650 | 159,430,660 | 160,392,805 | 158,936,251 | ||||||||||||
| CERTARA, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (UNAUDITED) | ||||||||
| (IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA) | DECEMBER 31, 2024 | DECEMBER 31, 2023 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 179,183 | $ | 234,951 | ||||
| Accounts receivable, net of allowances for credit losses of | 102,189 | 84,857 | ||||||
| Prepaid expenses and other current assets | 29,480 | 20,393 | ||||||
| Total current assets | 310,852 | 340,201 | ||||||
| Other assets: | ||||||||
| Property and equipment, net | 2,167 | 2,670 | ||||||
| Operating lease right-of-use assets | 13,841 | 9,604 | ||||||
| Goodwill | 757,038 | 716,333 | ||||||
| Intangible assets, net of | 485,214 | 487,043 | ||||||
| Deferred income taxes | 3,961 | 4,236 | ||||||
| Other long-term assets | 2,031 | 3,053 | ||||||
| Total assets | $ | 1,575,104 | $ | 1,563,140 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,502 | $ | 5,171 | ||||
| Accrued expenses | 56,451 | 56,779 | ||||||
| Current portion of deferred revenue | 77,829 | 60,678 | ||||||
| Current portion of long-term debt | 3,000 | 3,020 | ||||||
| Other current liabilities | 5,306 | 4,375 | ||||||
| Total current liabilities | 146,088 | 130,023 | ||||||
| Long-term liabilities: | ||||||||
| Deferred revenue, net of current portion | 1,049 | 1,070 | ||||||
| Deferred income taxes | 40,421 | 50,826 | ||||||
| Operating lease liabilities, net of current portion | 11,166 | 6,955 | ||||||
| Long-term debt, net of current portion and debt discount | 292,425 | 288,217 | ||||||
| Other long-term liabilities | 25,299 | 39,209 | ||||||
| Total liabilities | 516,448 | 516,300 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Preferred shares, | — | — | ||||||
| Common shares, | 1,620 | 1,603 | ||||||
| Additional paid-in capital | 1,216,925 | 1,178,461 | ||||||
| Accumulated deficit | (128,281 | ) | (116,230 | ) | ||||
| Accumulated other comprehensive loss | (13,424 | ) | (7,593 | ) | ||||
| Treasury stock at cost, 949,698 and 436,615 shares at December 31, 2024 and 2023, respectively | (18,184 | ) | (9,401 | ) | ||||
| Total stockholders' equity | 1,058,656 | 1,046,840 | ||||||
| Total liabilities and stockholders' equity | $ | 1,575,104 | $ | 1,563,140 | ||||
| CERTARA, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) | ||||||||
| TWELVE MONTHS ENDED DECEMBER 31, | ||||||||
| (IN THOUSANDS) | 2024 | 2023 | ||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (12,051 | ) | $ | (55,357 | ) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Depreciation and amortization of property and equipment | 1,994 | 1,552 | ||||||
| Amortization of intangible assets | 66,039 | 54,519 | ||||||
| Amortization of debt issuance costs | 1,035 | 1,527 | ||||||
| Provision for credit losses | 1,464 | 684 | ||||||
| Equity-based compensation expense | 34,774 | 28,300 | ||||||
| Change in fair value of contingent considerations | 8,089 | 24,118 | ||||||
| Goodwill impairment | — | 46,984 | ||||||
| Deferred income taxes | (12,695 | ) | (16,523 | ) | ||||
| Changes in assets and liabilities: | ||||||||
| Accounts receivable | (16,225 | ) | 152 | |||||
| Prepaid expenses and other assets | (2,873 | ) | 711 | |||||
| Accounts payable, accrued expenses, and other liabilities | (4,765 | ) | (5,607 | ) | ||||
| Deferred revenues | 13,834 | 28 | ||||||
| Other operating activities, net | 1,846 | 1,667 | ||||||
| Net cash provided by operating activities | 80,466 | 82,755 | ||||||
| Cash flows from investing activities: | ||||||||
| Capital expenditures | (1,625 | ) | (1,777 | ) | ||||
| Capitalized software development costs | (19,416 | ) | (13,491 | ) | ||||
| Investment in intangible assets | — | (54 | ) | |||||
| Business acquisitions, net of cash acquired | (91,327 | ) | (64,228 | ) | ||||
| Net cash used in investing activities | (112,368 | ) | (79,550 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from borrowings on term loan debt | 6,305 | — | ||||||
| Payment of debt issuance costs | (1,216 | ) | — | |||||
| Payments on long-term debt and finance lease obligations | (2,255 | ) | (3,045 | ) | ||||
| Payments for business acquisition related contingent consideration | (15,156 | ) | — | |||||
| Payment of taxes on shares withheld for employee taxes | (8,688 | ) | (6,402 | ) | ||||
| Net cash used in financing activities | (21,010 | ) | (9,447 | ) | ||||
| Effect of foreign exchange rate on cash and cash equivalents | (2,856 | ) | 1,505 | |||||
| Net increase (decrease) in cash and cash equivalents | (55,768 | ) | (4,737 | ) | ||||
| Cash and cash equivalents at beginning of period | 234,951 | 239,688 | ||||||
| Cash and cash equivalents at end of period | $ | 179,183 | $ | 234,951 | ||||
NON-GAAP FINANCIAL MEASURES
The following table reconciles net loss to adjusted EBITDA:
| THREE MONTHS ENDED DECEMBER 31, | TWELVE MONTHS ENDED DECEMBER 31, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||
| (in thousands) | ||||||||||||||
| Net income (loss)(a) | $ | 6,577 | $ | (12,456 | ) | $ | (12,051 | ) | $ | (55,357 | ) | |||
| Interest expense(a) | 5,004 | 5,870 | 21,520 | 22,916 | ||||||||||
| Interest income(a) | (1,365 | ) | (2,889 | ) | (9,034 | ) | (9,317 | ) | ||||||
| (Benefit from) Provision for income taxes(a) | (4,397 | ) | 72 | (5,133 | ) | 214 | ||||||||
| Depreciation and amortization expense(a) | 672 | 413 | 1,994 | 1,552 | ||||||||||
| Intangible asset amortization(a) | 17,544 | 14,420 | 66,039 | 54,519 | ||||||||||
| Currency (gain) loss(a) | (182 | ) | 803 | 2,344 | 638 | |||||||||
| Equity-based compensation expense(b) | 7,731 | 7,502 | 34,774 | 28,300 | ||||||||||
| Change in fair value of contingent consideration(d) | (3 | ) | 12,802 | 8,089 | 24,118 | |||||||||
| Goodwill impairment expense(e) | — | — | — | 46,984 | ||||||||||
| Acquisition-related expenses(f) | 1,275 | 2,788 | 5,426 | 6,064 | ||||||||||
| Integration expense(g) | — | (69 | ) | — | 121 | |||||||||
| Transaction-related expenses(h) | — | — | 2,625 | — | ||||||||||
| Severance expenses(i) | — | — | 183 | — | ||||||||||
| Reorganization expense(j) | 279 | 58 | 4,223 | 1,660 | ||||||||||
| Loss on disposal of fixed assets(k) | 388 | 36 | 401 | 65 | ||||||||||
| Executive recruiting expense(l) | 1 | 235 | 646 | 631 | ||||||||||
| Adjusted EBITDA | $ | 33,524 | $ | 29,585 | $ | 122,046 | $ | 123,108 | ||||||
The following table reconciles net loss to adjusted net income:
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||
| (in thousands) | ||||||||||||||
| Net income (loss) (a) | $ | 6,577 | $ | (12,456 | ) | $ | (12,051 | ) | $ | (55,357 | ) | |||
| Currency (gain) loss(a) | (182 | ) | 803 | 2,344 | 638 | |||||||||
| Equity-based compensation expense(b) | 7,731 | 7,502 | 34,774 | 28,300 | ||||||||||
| Amortization of acquisition-related intangible assets(c) | 14,390 | 11,946 | 54,431 | 45,838 | ||||||||||
| Change in fair value of contingent consideration(d) | (3 | ) | 12,802 | 8,089 | 24,118 | |||||||||
| Goodwill impairment expense(e) | — | — | — | 46,984 | ||||||||||
| Acquisition-related expenses(f) | 1,275 | 2,788 | 5,426 | 6,064 | ||||||||||
| Integration expense(g) | — | (69 | ) | — | 121 | |||||||||
| Transaction - related expenses (h) | — | — | 2,625 | — | ||||||||||
| Severance expense(i) | — | — | 183 | — | ||||||||||
| Reorganization expense(j) | 279 | 58 | 4,223 | 1,660 | ||||||||||
| Loss on disposal of fixed assets(k) | 388 | 36 | 401 | 65 | ||||||||||
| Executive recruiting expense(l) | 1 | 235 | 646 | 631 | ||||||||||
| Income tax expense impact of adjustments(m) | (5,778 | ) | (9,372 | ) | (28,220 | ) | (30,041 | ) | ||||||
| Adjusted net income | $ | 24,678 | $ | 14,273 | $ | 72,871 | $ | 69,021 | ||||||
The following tables reconciles diluted earnings per share to adjusted diluted earnings per share:
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||
| (In thousands, except share and per share data) | ||||||||||||||
| Diluted earnings per share(a) | $ | 0.04 | $ | (0.08 | ) | $ | (0.08 | ) | $ | (0.35 | ) | |||
| Currency (gain) loss(a) | — | 0.01 | 0.02 | — | ||||||||||
| Equity-based compensation expense(b) | 0.05 | 0.05 | 0.22 | 0.18 | ||||||||||
| Amortization of acquisition-related intangible assets(c) | 0.09 | 0.07 | 0.34 | 0.29 | ||||||||||
| Change in fair value of contingent consideration(d) | — | 0.08 | 0.05 | 0.15 | ||||||||||
| Goodwill impairment expense(e) | — | — | — | 0.30 | ||||||||||
| Acquisition-related expenses(f) | 0.01 | 0.02 | 0.03 | 0.04 | ||||||||||
| Integration expense(g) | — | — | — | — | ||||||||||
| Transaction - related expenses (h) | — | — | 0.02 | — | ||||||||||
| Severance expense(i) | — | — | — | — | ||||||||||
| Reorganization expense(j) | — | — | 0.03 | 0.01 | ||||||||||
| Loss on disposal of fixed assets(k) | — | — | — | — | ||||||||||
| Executive recruiting expense(l) | — | — | — | — | ||||||||||
| Income tax expense impact of adjustments(m) | (0.04 | ) | (0.06 | ) | (0.18 | ) | (0.19 | ) | ||||||
| Adjusted Diluted Earnings Per Share | $ | 0.15 | $ | 0.09 | $ | 0.45 | $ | 0.43 | ||||||
| Basic weighted average common shares outstanding | 160,891,458 | 159,430,660 | 160,392,805 | 158,936,251 | ||||||||||
| Effect of potentially dilutive shares outstanding (n) | 374,192 | 544,784 | 635,547 | 943,886 | ||||||||||
| Adjusted diluted weighted average common shares outstanding | 161,265,650 | 159,975,444 | 161,028,352 | 159,880,137 | ||||||||||
The following tables reconcile revenues to the revenues adjusted for constant currency:
| THREE MONTHS ENDED DECEMBER 31, | Change | ||||||||||||||||||||||||||
| 2024 | 2024 | 2023 | $ | % | $ | % | |||||||||||||||||||||
| Actual | CC | Actual | Actual | Actual | CC Impact | Adjust for CC | |||||||||||||||||||||
| (GAAP) | (non-GAAP) | (GAAP) | (GAAP) | (GAAP) | (non-GAAP) | (non-GAAP) | |||||||||||||||||||||
| (in thousands, except percentage) | |||||||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||||||
| Software | $ | 42,270 | $ | 42,278 | $ | 33,619 | $ | 8,651 | 26 | % | $ | 8 | 26 | % | |||||||||||||
| Services | 58,091 | 57,940 | 54,391 | 3,700 | 7 | % | (151 | ) | 7 | % | |||||||||||||||||
| Total Revenue | $ | 100,361 | $ | 100,218 | $ | 88,010 | $ | 12,351 | 14 | % | $ | (143 | ) | 14 | % | ||||||||||||
| TWELVE MONTHS ENDED DECEMBER 31, | Change | ||||||||||||||||||||||||||
| 2024 | 2024 | 2023 | $ | % | $ | % | |||||||||||||||||||||
| Actual | CC | Actual | Actual | Actual | CC Impact | Adjust for CC | |||||||||||||||||||||
| (GAAP) | (non-GAAP) | (GAAP) | (GAAP) | (GAAP) | (non-GAAP) | (non-GAAP) | |||||||||||||||||||||
| (in thousands, except percentage) | |||||||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||||||
| Software | $ | 155,696 | $ | 155,192 | $ | 131,677 | $ | 24,019 | 18 | % | $ | (504 | ) | 18 | % | ||||||||||||
| Services | 229,452 | 228,651 | 222,660 | 6,792 | 3 | % | (801 | ) | 3 | % | |||||||||||||||||
| Total Revenue | $ | 385,148 | $ | 383,843 | $ | 354,337 | $ | 30,811 | 9 | % | $ | (1,305 | ) | 8 | % | ||||||||||||
| (a.) | All measures are amounts determined under GAAP. |
| (b.) | Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy. |
| (c.) | Represents amortization costs associated with acquired intangible assets in connection with business acquisitions. |
| (d.) | Represents expense associated with remeasuring fair value of contingent consideration of business acquisition. |
| (e.) | Represents expense associated with goodwill impairment charge. |
| (f.) | Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions. |
| (g.) | Represents integration costs related to post - acquisition integration activities. |
| (h.) | Represents costs associated with our public offerings that are not capitalized, as well as debt issuance costs that are not deferred or treated as a contra-liability directly deducted from the carrying value of the associated debt liability. |
| (i.) | Represents charges for severance provided to former executives. |
| (j.) | Represents expense related to reorganization, including legal entity reorganization and lease abandonment cost associated with the evaluation of our office space footprint |
| (k.) | Represents the gain/loss related to disposal of fixed assets. |
| (l.) | Represents recruiting and relocation expenses related to hiring senior executives. |
| (m.) | Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction. |
| (n.) | Represents potentially dilutive shares that were included from our GAAP diluted weighted average common shares outstanding. |
FAQ
What was Certara's (CERT) revenue growth in Q4 2024?
How much did Certara's (CERT) software revenue increase in Q4 2024?
What is Certara's (CERT) revenue guidance for 2025?
How did Certara's (CERT) bookings perform in Q4 2024?
What was Certara's (CERT) net income in Q4 2024?
